Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.

Abstract excerpt

Lung adenocarcinoma (LADC) is a cancer treatable using targeted therapies against driver gene aberrations. EGFR mutations and ALK fusions are frequent gene aberrations in LADC, and personalized therapies against those aberrations have become a standard therapy. These targeted therapies have shown significant positive efficacy and tolerable toxicity compared to conventional chemotherapy, so it is necessary to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anaplastic Lymphoma Kinase
• Share to Gene Fusion
• Share to Immunotherapy